Clinical researchLong-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years
Section snippets
Methods
Patients with symptomatic obstructive HCM (New York Heart Association [NYHA] class ≥ II) receiving maximum medical therapy were consecutively enrolled between January 1999 and December 2005. All patients had to have a basal septal thickness > 15 mm and maximal left ventricular (LV) outflow pressure gradient > 30 mm Hg at rest or > 50 mm Hg under provocation (application of isosorbide dinitrate in sublingual form). Seventy-six patients were randomized into 2 arms in a 1:1 ratio and subsequently
Results
In a total of 76 patients, we ablated 86 septal branches in 80 ASA procedures. In the low-dose group, 39 ASA procedures were performed on 37 patients. Similarly, in the high-dose group, 41 ASA procedures were performed on 39 patients (2 repeat procedures in each group). Alcohol injection volumes were 1.1 ± 0.2 and 2.5 ± 0.8 mL (P < 0.01). The subsequent CK-MB peak was 1.7 ± 0.8 vs 2.6 ± 1.3 μkatal/L (P < 0.01). There was a moderate correlation between peak CK-MB and the amount of alcohol used (r
Discussion
This study demonstrates that ASA treatment for obstructive HCM is safe and effective in the long-term. No differences were found between patients treated with low or high doses of alcohol with respect to the long-term efficacy and safety of ASA. Interestingly, Lawrenz et al. have presented recently that reduction of alcohol dose below 1 mL resulted in lower myocardial damage (biomarker release), but the residual gradient was unsatisfactorily high. On the other hand, a mean dose 1.4 mL led both
Conclusion
This study demonstrates that ASA for obstructive HCM is safe and effective in long-term follow-up. No differences in long-term efficacy and safety were found between low and high doses of alcohol.
Funding Sources
This work was supported by a grant from the Ministry of Health of the Czech Republic VZFNM2005 and NT/11401-5/2011.
Disclosures
The authors have no conflicts of interest to disclose.
References (18)
- et al.
Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy
J Am Coll Cardiol
(2011) - et al.
Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes
Am J Cardiol
(2005) Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy
Lancet
(1995)The history of alcohol septal ablation
Cardiovasc Revasc Med
(2010)- et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic CardiomyopathyA report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur Heart J
(2003) - et al.
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy
Circulation
(2008) - et al.
Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy
Circulation
(2004) - et al.
Septal myectomy for hypertrophic obstructive cardiomyopathy: coil, boil and the role of rescue surgery
Eur J Cardiothorac Surg
(2009) - et al.
Echo-guided percutaneous septal ablation for symptomatic hypertrophic cardiomyopathy: 7 years of experience
Eur J Echocardiogr
(2004)
Cited by (45)
Reply to Dai—Severe Left Ventricular Obstruction Is No Limitation for Alcohol Septal Ablation
2024, Canadian Journal of CardiologyLooking Back at 30 Years of Alcohol Septal Ablation and Looking Forward to the Future
2024, Canadian Journal of CardiologyThe less-is-better effect: The case of alcohol dose in septal ablation for hypertrophic cardiomyopathy
2021, International Journal of CardiologyAlcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy
2021, International Journal of CardiologyCitation Excerpt :These investigators concluded that patients who were given a higher amount of alcohol (>2 mL) had a higher mortality rate than those given lower doses [15]. Subsequently, a small, single-center, prospective, randomized study did not find any differences in hemodynamic effects and long-term survival between patients with low- and high doses of alcohol [10,11]. Similarly, Liebregts et al. retrospectively evaluated patients treated in a non-randomized fashion with low- (≤2 mL) or high-dose (>2 mL) of alcohol (n = 267) and found that the long-term survival and rates of adverse arrhythmic events were similar [16].
Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
2018, Canadian Journal of CardiologyNew Developments in Hypertrophic Cardiomyopathy
2017, Canadian Journal of Cardiology
See editorial by Kuhn, pages 668-670 in this issue.
See page 766 for disclosure information.